stockrow
Friday 6 November 2026
Export CLNN’s income statement to Excel — free account
Clene Inc.
CLNN Healthcare Biotechnology
Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024.
- Revenue
- +273.3%
- EPS
- +135.2%
- Free cash flow
- −16.6%
- Total debt
- −60.3%
Quarter to September 2026, against a year earlier
3.85
0.12
−3.02%
Follow CLNN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | 1 | 0 | 1 | 0 | 0 | 0 | (0.6%) | 0 | 3 | 24 | +394.6% | |
| Gross margin, % | — | — | — | 0.00 | 68.45 | 60.03 | 94.50 | 81.50 | 79.53 | 78.50 | 68.49 | +78.5 pt | ||||||
| EBT | — | 0 | 0 | (16) | (19) | (10) | (30) | (50) | (39) | (26) | (27) | n/m | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | (9,160.68) | (1,406.36) | (6,325.16) | (7,569.42) | (11,520.47) | (13,086.50) | (11,271.43) | (13,086.5) pt | ||||||
| Net income | — | 0 | 0 | (16) | (19) | (10) | (30) | (50) | (39) | (26) | (27) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.24 | 0.23 | 0.15 | 0.12 | 0.05 | 0.02 | 0.02 | n/m | |||||
| Earnings | — | 0.00 | (4.00) | (18.61) | (22.00) | (3.20) | (9.20) | (9.40) | (5.67) | (2.65) | (2.35) | n/m | ||||||
| Cash flow | — | 0.00 | (3.02) | (15.21) | (21.63) | (11.25) | (11.97) | (5.75) | (3.07) | (1.88) | (1.26) | n/m | ||||||
| Capex | — | 0.00 | 0.00 | (0.34) | (0.44) | (0.43) | (1.59) | (0.06) | 0.00 | 0.00 | (0.01) | n/m | ||||||
| Free cash flow | — | 0.00 | (3.02) | (15.54) | (22.07) | (11.68) | (13.55) | (5.81) | (3.07) | (1.89) | (1.27) | n/m | ||||||
| Book value | — | 0.00 | 73.64 | (78.09) | 0.39 | 4.09 | 0.99 | 2.55 | (1.27) | (1.78) | (1.13) | n/m | ||||||
| Shares, m | — | 2 | 0 | 1 | 1 | 3 | 3 | 5 | 7 | 10 | 12 | +22.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 765.59 | 349.08 | 130.96 | 47.17 | 107.97 | 289.36 | 211.59 | 281.7 | ||||||
| P/B | — | — | — | — | 462.50 | 20.04 | 19.14 | 2.30 | 0.00 | 0.00 | 0.00 | 84.0 | ||||||
| EV/Sales | — | — | — | — | 488.30 | 306.06 | 122.45 | 12.09 | 117.53 | 331.12 | 196.34 | 229.6 | ||||||
| EV/FCF | — | — | — | — | (5.21) | (6.15) | (1.31) | (0.26) | (1.88) | (3.56) | (2.81) | (3.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | 0 | (13) | (19) | (35) | (39) | (30) | (21) | (19) | (17) | n/m | |||||
| Capex | — | 0 | — | 0 | 0 | (1) | (5) | 0 | 0 | 0 | 0 | n/m | ||||||
| Free cash flow | — | 0 | 0 | (13) | (19) | (36) | (44) | (31) | (21) | (19) | (17) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 0 | 1 | 5 | 51 | 49 | 15 | 14 | 6 | (2) | (3) | +128.7% | |||||
| Net debt | — | — | (1) | (8) | (57) | (31) | (4) | (23) | 3 | 8 | (4) | n/m | ||||||
| Shareholders’ equity | — | 0 | 5 | (68) | 0 | 13 | 3 | 13 | (9) | (18) | (15) | +204.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | 0.00 | (1.17) | (52.08) | (46.38) | (14.84) | (55.63) | (102.25) | (98.90) | (115.13) | (120.65) | (115.1) pt | |||||
| ROIC | — | 0.00 | (4.76) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | 0.00 | (11.10) | 51.47 | 57.17 | (150.56) | (377.90) | (595.47) | (1,738.36) | 197.91 | 197.50 | +197.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 74 | 102 | 86 | 85 | 76 | 79 | — | +1.3% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | — | (1.9%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026
Clene Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CRDF Cardiff Oncology, Inc. | $58.8M | — (loss-making) | — (loss-making) | −14.05% (below 0%: shrinking) | n/m | −41.36% (below 0%: shrinking) | 100.00% | (9,245.19%) | Compare |
| GOSS Gossamer Bio, Inc. | $57.6M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| TELO Telomir Pharmaceuticals, Inc. | $57.5M | — (loss-making) | — | — | n/m | −45.34% (below 0%: shrinking) | — | 0.00% | Compare |
| XBIT XBiotech Inc. | $57.0M | — (loss-making) | — (loss-making) | −93.33% (below 0%: shrinking) | n/m | +25.25% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLNN Clene Inc. | $56.4M | — (loss-making) | — (loss-making) | +273.33% (above 0%: growing) | n/m | −16.61% (below 0%: shrinking) | 71.43% | (11,333.93%) | |
| XLO Xilio Therapeutics, Inc. | $55.9M | — (loss-making) | — (loss-making) | +131.22% (above 0%: growing) | n/m | −26.23% (below 0%: shrinking) | 100.00% | (18.68%) | Compare |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | $55.3M | — (loss-making) | — (loss-making) | −92.09% (below 0%: shrinking) | n/m | −78.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BOLD Boundless Bio, Inc. | $54.8M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | Compare |
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +300.75% (above 0%: growing) | n/m | −12.69% (below 0%: shrinking) | 82.36% | (303.56%) | Compare |
| Median of peers | $56.5M | — | — | −16.82% | — | −33.79% | 91.18% | (9.34%) |